These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27209475)

  • 1. In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors.
    Asadollahi-Baboli M
    Mol Divers; 2016 Aug; 20(3):729-39. PubMed ID: 27209475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
    Qin X; Li Z; Yang L; Liu P; Hu L; Zeng C; Pan Z
    Bioorg Med Chem; 2016 Jul; 24(13):2871-2881. PubMed ID: 27234887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures.
    Sato T; Watanabe H; Tsuganezawa K; Yuki H; Mikuni J; Yoshikawa S; Kukimoto-Niino M; Fujimoto T; Terazawa Y; Wakiyama M; Kojima H; Okabe T; Nagano T; Shirouzu M; Yokoyama S; Tanaka A; Honma T
    Bioorg Med Chem; 2012 Jun; 20(12):3756-67. PubMed ID: 22607878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
    Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C
    Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pamanji R; Yeguvapalli S
    J Recept Signal Transduct Res; 2018 Feb; 38(1):48-60. PubMed ID: 29369008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
    Davis GD; Vasanthi AH
    Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homology models of the mutated EGFR and their response towards quinazoline analogues.
    Kotra S; Madala KK; Jamil K
    J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
    Michalczyk A; Klüter S; Rode HB; Simard JR; Grütter C; Rabiller M; Rauh D
    Bioorg Med Chem; 2008 Apr; 16(7):3482-8. PubMed ID: 18316192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
    Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
    Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
    Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
    Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of B-Raf[Formula: see text] inhibitors using 2D and 3D-QSAR, molecular docking and pharmacophore studies.
    Aalizadeh R; Pourbasheer E; Ganjali MR
    Mol Divers; 2015 Nov; 19(4):915-30. PubMed ID: 26276566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer.
    Zhang F; Zhang H; Wang F
    J BUON; 2016; 21(6):1482-1490. PubMed ID: 28039712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico target specific design of potential quinazoline-based anti-NSCLC agents.
    Mohammadnejadi E; Razzaghi-Asl N
    J Biomol Struct Dyn; 2023 Dec; 41(20):10725-10736. PubMed ID: 36826424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QSAR analysis of tyrosine kinase inhibitor using modified ant colony optimization and multiple linear regression.
    Shi WM; Shen Q; Kong W; Ye BX
    Eur J Med Chem; 2007 Jan; 42(1):81-6. PubMed ID: 16996653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR.
    Chauhan JS; Dhanda SK; Singla D; ; Agarwal SM; Raghava GP
    PLoS One; 2014; 9(7):e101079. PubMed ID: 24992720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors.
    Lü S; Zheng W; Ji L; Luo Q; Hao X; Li X; Wang F
    Eur J Med Chem; 2013 Mar; 61():84-94. PubMed ID: 22867529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines.
    Hamed MM; Abou El Ella DA; Keeton AB; Piazza GA; Abadi AH; Hartmann RW; Engel M
    ChemMedChem; 2013 Sep; 8(9):1495-504. PubMed ID: 23847159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
    Lin J; Shen W; Xue J; Sun J; Zhang X; Zhang C
    Eur J Med Chem; 2012 Sep; 55():39-48. PubMed ID: 22818848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.